Investor Presentaiton slide image

Investor Presentaiton

Investor Presentation First nine months of 2018 Slide 37 Region China at a glance Diabetes trend in population Population with diabetes Diabetes market by value and Novo Nordisk market share Novo Nordisk reported sales Million Diabetes growth rate 160 NN Insulin MS NN OAD MS bDKK 24- NN GLP-1 MS First nine months of 2018 Sales (mDKK) YTD growth² 100% 5% Long-acting insulin³ 619 21% 495% Premix insulin4 2,870 9% GLP-1 80% 120 Fast-acting insulin5 1,105 19% I 125 32.5%1 119 16 Human insulin 2,144 (7%) 60% Total insulin 6,738 6% 80 12.5%¹ Insulin 40% GLP-16 388 89% 80 40 20 0 0 2000 2017 2045 Aug 2013 12.5%¹ OAD - 20% 0% Other diabetes care? Diabetes care Obesity (SaxendaⓇ) Biopharm³ 1,284 6% 8,410 8% 163 Aug 2018 Total 8,573 (4%) 8% China population 2018: ~1.4 billion people and diabetes prevalence ~10.9% Source: International Diabetes Federation: Diabetes Atlas 1th Edition 2000 and Diabetes Atlas 8th Edition 2017 1 CAGR calculated for last 5-year period Competitor value market share for insulin as of Aug 2018: Sanofi 18% and Gan & Lee 12% Competitor value market share for GLP-1 as of Aug 2018: AstraZeneca 17% OAD: Oral anti-diabetic; MS: Market share Source: IQVIA MAT Aug, 2018 value figures 2 Percentage change in local currency from YTD Q3 2017 to YTD Q3 2018 3 Comprises TresibaⓇ and Levemir®; 4 Comprises NovoMix®; 5 Comprises NovoRapidⓇ; 6 Comprises Victoza®; 7 Comprises Novo NormⓇ and needles; 8 Comprises primarily NovoSeven®, NovoEight® and Norditropin®
View entire presentation